ScoreWhy is Marksans Pharma Ltd ?
1
High Management Efficiency with a high ROE of 15.04%
2
The company is Net-Debt Free
3
Positive results in Mar 26
- CASH AND CASH EQUIVALENTS(HY) Highest at Rs 989.65 cr
- NET SALES(Q) Highest at Rs 856.11 cr
- PBDIT(Q) Highest at Rs 195.42 cr.
4
High Institutional Holdings at 23.34%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 9.3% over the previous quarter.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Marksans Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Marksans Pharma for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Marksans Pharma
-3.57%
-0.09
40.55%
Sensex
-5.98%
-0.45
13.24%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
16.48%
EBIT Growth (5y)
10.60%
EBIT to Interest (avg)
30.23
Debt to EBITDA (avg)
0.40
Net Debt to Equity (avg)
-0.21
Sales to Capital Employed (avg)
1.05
Tax Ratio
25.06%
Dividend Payout Ratio
8.67%
Pledged Shares
0
Institutional Holding
23.34%
ROCE (avg)
26.15%
ROE (avg)
15.04%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
27
Industry P/E
34
Price to Book Value
3.74
EV to EBIT
21.24
EV to EBITDA
17.75
EV to Capital Employed
4.49
EV to Sales
3.61
PEG Ratio
2.76
Dividend Yield
0.32%
ROCE (Latest)
21.13%
ROE (Latest)
13.82%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend18What is working for the Company
CASH AND CASH EQUIVALENTS(HY)
Highest at Rs 989.65 cr
NET SALES(Q)
Highest at Rs 856.11 cr
PBDIT(Q)
Highest at Rs 195.42 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 22.83%
PBT LESS OI(Q)
Highest at Rs 164.83 cr.
PAT(Q)
Highest at Rs 148.13 cr.
EPS(Q)
Highest at Rs 3.27
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Marksans Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 164.83 cr has Grown at 59.3% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 103.49 CrMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 148.13 cr has Grown at 64.4% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 90.08 CrMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 856.11 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Net Sales - Quarterly
At Rs 856.11 cr has Grown at 22.2% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 700.82 CrMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 195.42 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 22.83%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 164.83 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 148.13 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 3.27
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Cash and Cash Equivalents - Half Yearly
Highest at Rs 989.65 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Here's what is not working for Marksans Pharma
Non Operating Income - Quarterly
Highest at Rs 35.17 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
